Variant Bio
PrivateLast Round
Series B
Nov 1, 2021
Est. Valuation
$225M
Total Funding Raised
$122.5M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Variant Bio operates in Healthcare & Life Sciences and is based in Seattle, Washington. Its latest recorded funding round was a Series B round in November 2021.
Variant Bio is a biotechnology company that develops life-saving therapies by studying the genes of people with exceptional health-related traits.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology, Precision Medicine, Medical AI
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Variant Bio Comparables
Compare Variant Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| BenevolentAI | 83% | |
| Valo Health | 83% | |
| Quotient Therapeutics | 82% |
For institutional investors. Book with your work email.
Variant Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Nov 1, 2021 | ||||
| Series A | May 28, 2020 | ||||
| Seed | Oct 1, 2018 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Variant Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| SoftBank Investment Advisers | Series B |
| Vulcan Capital | Series B |
| SoftBank Group | Series B |
| Lux Capital | Series B, Seed, Series A |
| Biomatics Capital Partners | Series A |
| General Catalyst | Series B |
| Cercano Management | Series B |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors increased 87% MoM.
- Jan 21, 2026
Craig T. Basson appointed Chief Medical Officer and President of R&D.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- licenses_technologySep 29, 2026
In Oct '26, Variant Bio and Boehringer Ingelheim Pharmaceuticals, Inc. expand their multi-year research and license agreement from kidney disease into cardiovascular target discovery in an agreement potentially worth more than $250M.
For institutional investors. Book with your work email.
Variant Bio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Variant Bio's valuation, stock price, and market status.
Is Variant Bio a public or private company?
Variant Bio is a private company.
What is the current stock price of Variant Bio?
Variant Bio is a private company, so its shares have no public market price. Caplight tracks Variant Bio's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Variant Bio worth (valuation)?
Variant Bio's valuation is estimated at $225.0M based on funding round data.
Can I buy Variant Bio stock?
Variant Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Variant Bio's last funding round?
Variant Bio's most recent funding round was Series B on November 1, 2021.
Who are the main investors in Variant Bio?
Key investors in Variant Bio include SoftBank Investment Advisers, SoftBank Group, Lux Capital.
Will Variant Bio IPO soon?
No public IPO plans have been announced for Variant Bio.
How can I track Variant Bio secondary market activity?
Caplight tracks bids, offers, and trades in Variant Bio's shares on secondary markets.